• Corpus ID: 5827079

[Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality].

@article{Balant1976PharmacokineticsOT,
  title={[Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality].},
  author={Luc P. Balant and A. Gorgia and Jean-Marie Tschopp and Claude Revillard and Jean Fabre},
  journal={Schweizerische medizinische Wochenschrift},
  year={1976},
  volume={106 41},
  pages={
          1403-7
        }
}
10 healthy male volunteers received orally either 100 mg tolamolol or 20 mg bufuralol. These experiments were repeated by intravenous administration of 10 and 5 mg respectively of these two drugs. Plasma levels of the parent drugs and their main metabolite were measured. In one subject, the apparent half-life of elimination was increased from 2.5 h (normal subjects) to 5 h for both drugs. This prolongation of the half-life is associated with low plasma levels of the metabolites, a peculiarity… 
20 Citations
The polymorphic oxidation of beta-adrenoceptor antagonists.
  • M. Lennard
  • Biology, Medicine
    Pharmacology & therapeutics
  • 1989
Influence of renal failure on the hepatic clearance of bufuralol in man
TLDR
From this analysis it appears that the presystemic biotransformation of bufuralol is decreased in renal failure and that changes in systemic clearance are compensated in patients by modifications of the volume of distribution, resulting in little net change in the halflife of elimination.
The genetic controlof bufuralol metabolisminman
TLDR
Determination of the plasma metabolic ratio in the family of this subject and in a larger population confirmed that aliphatic hydroxylation of bufuralol is under polymorphic control.
THE DURATION OF ACTION OF PINDOLOL and ITS RELATION TO PLASMA LEVELS
TLDR
The purpose of the present study was to investigate the relationship between blood levels of pindolol and its pharmacological effect, and to assess whether the existence of such a relationship has any clinical significance.
The Polymorphic Oxidation of β-Adrenoceptor Antagonists
TLDR
Debrisoquine oxidation phenotype is a major determinant of the metabolism, pharmacokinetics and some of the pharmacological actions of metoprolol, bufuralol, timolol and bopindolol, and the disposition of atenolol which is eliminated predominantly unchanged by the kidney and in the faeces, is unrelated to debrisoquine phenotype.
Oxidation phenotype and the metabolism and action of beta-blockers
  • M. Lennard
  • Biology, Medicine
    Klinische Wochenschrift
  • 2005
TLDR
Variability in response to some drugs such as debrisoquine can be attributed to genetic polymorphism of their oxidative metabolism, which is a major determinant of the metabolism, pharmacokinetics and some of the pharmacological actions of metoprolol, bufuralol and timolol.
Polymorphic metabolism of beta-adrenoceptor antagonists.
TLDR
Oxidation phenotype correlates well with intensity and duration of beta-adrenoceptor blockade after metoprolol, PM subjects requiring only once-daily dosing, however, in EM subjects twice- daily dosing is required even if slow release preparations are used, since plasma metoprool concentrations may remain negligible 24 h after dosing.
Inter-ethnic differences in dose-response studies
TLDR
Inter-ethnic investigations in Phase I and II studies should provide information on dose-concentration-response relationships and investigations of pharmacokinetics and pharmacodynamics in both preclinical and clinical studies can produce an early identification of optimal dosing regimens thus shortening the overall time for drug development.
Pharmacodynamic and pharmacokinetic studies on bufuralol in man.
TLDR
Findings show that bufuralol is a potent beta-adrenoceptor antagonist with partial agonist activity that has a long duration of action and there is bimodal metabolism of the drug in man.
...
1
2
...